文献速递关节外科

年轻患者髌股关节置换与全膝关节置换的成本效益比较

Cost effectiveness of patellofemoral versus total knee arthroplasty in younger patients.
PubMed 文献 · Bone Joint J · 2017-01-01

研究采用马尔可夫模型,比较美国人群中60岁和50岁模拟患者行髌股关节置换(PFA)与全膝关节置换(TKA)治疗孤立性髌股骨关节炎的成本效益,从医疗付费方角度计算终身成本、质量调整生命年(QALY)和增量成本效果比(ICER)。PFA更贵(49811美元 vs 46632美元)但更有效(14.3 QALY vs 13.3 QALY),ICER为3097美元。结论认为PFA近期生存率改善使其在年轻患者中成为有经济益处的保关节手术。

要点

  • PFA终身成本49811美元,高于TKA的46632美元,但获得14.3 QALY,高于TKA的13.3 QALY。
  • PFA额外效果的ICER为3097美元,低于50000美元/QALY的支付意愿阈值。
  • 当PFA效用值超过TKA至少1.0%时,PFA仍具成本效益;年翻修率降低24.5%时,PFA以不增加成本提供增量获益。

核心结论

  • 近期假体生存率的改善使PFA在年轻患者中成为有经济益处的保关节手术,可延迟TKA直至假体失败或胫股骨关节炎进展。

研究设计与样本

  • 采用马尔可夫状态转换模型,比较PFA与TKA的成本效益,模拟患者年龄为60岁(基础病例)和50岁。
  • 从医疗付费方角度计算终身成本(2015年美元)、QALY增益和ICER,年翻修率来自英格兰、威尔士、北爱尔兰和马恩岛的国家关节登记系统。
  • 对所有参数进行确定性和概率敏感性分析,支付意愿阈值为50000美元/QALY。

主要发现

  • PFA终身成本为49811美元,高于TKA的46632美元;PFA获得14.3 QALY,高于TKA的13.3 QALY。
  • PFA额外效果对应的ICER为3097美元。
  • 模型主要对效用值敏感,当PFA效用值超过TKA至少1.0%时,PFA仍具成本效益。
  • 当年翻修率降低24.5%时,PFA以不增加成本提供增量获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patellofemoral arthroplasty (PFA) has experienced significant improvements in implant survivorship with second generation designs. This has renewed interest in PFA as an alternative to total knee arthroplasty (TKA) for younger active patients with isolated patellofemoral osteoarthritis (PF OA). We analysed the cost-effectiveness of PFA versus TKA for the management of isolated PF OA in the United States-based population. PATIENTS AND METHODS: We used a Markov transition state model to compare cost-effectiveness between PFA and TKA. Simulated patients were aged 60 (base case) and 50 years. Lifetime costs (2015 United States dollars), quality-adjusted life year (QALY) gains and incremental cost-effectiveness ratio (ICER) were calculated from a healthcare payer perspective. Annual rates of revision were derived from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Deterministic and probabilistic sensitivity analysis was performed for all parameters against a $50 000/QALY willingness to pay. RESULTS: PFA was more expensive ($49 811 versus $46 632) but more effective (14.3 QALYs versus 13.3 QALYs) over a lifetime horizon. The ICER associated with the additional effectiveness of PFA was $3097. The model was mainly sensitive to utility values, with PFA remaining cost-effective when its utility exceeded that of TKA by at least 1.0%. PFA provided incremental benefits at no increased cost when annual rates of revision decreased by 24.5%. CONCLUSIONS: Recent improvements in rates of implant of survival have made PFA an economically beneficial joint-preserving procedure in younger patients, delaying TKA until implant failure or tibiofemoral OA progression. The present study quantified the minimum required marginal benefit for PFA to be cost-effective compared with TKA and identified survivorship targets for PFA to become both less expensive and more effective. These benchmarks might be used to assess clinical outcomes of PFA from an economic standpoint within the United States healthcare system. Cite this article: Bone Joint J 2017;99-B:1028-36.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Chawla H, Nwachukwu BU, van der List JP, et al. Cost effectiveness of patellofemoral versus total knee arthroplasty in younger patients. Bone Joint J. 2017. PMID: 28768779. doi:10.1302/0301-620X.99B8.BJJ-2016-1032.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。